Clinical Trials
6 trialsNCT05564377 2026-06-02
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04553133 2026-05-06
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
Phase 2 Active not recruiting
NCT06494150 2026-02-23
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
University of Oklahoma
Phase 2 Recruiting
NCT05082025 2026-01-09
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05113368 2025-08-21
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT00617188 2017-12-28
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Completed